This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, D. N.
Right arrow Articles by Bourgeois, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, D. N.
Right arrow Articles by Bourgeois, A. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2008, p. 1179-1181, Vol. 52, No. 3
0066-4804/08/$08.00+0     doi:10.1128/AAC.01108-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Systemic Pharmacokinetics of Rifaximin in Volunteers with Shigellosis{triangledown}

David N. Taylor,1,2* Robin McKenzie,1 Anna Durbin,1 Colleen Carpenter,1 Robert Haake,2 and A. Louis Bourgeois1

Center for Immunization Research, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland,1 Salix Pharmaceuticals, Inc., Morrisville, North Carolina2

Received 22 August 2007/ Returned for modification 24 October 2007/ Accepted 1 December 2007

Rifaximin is an oral antibiotic indicated for treatment of traveler's diarrhea. Rifaximin pharmacokinetics were evaluated in individuals challenged with Shigella flexneri. Peak plasma rifaximin concentrations were low after nine consecutive doses, and no accumulation was observed. Rifaximin serum levels were minimal and similar to those previously reported in studies of healthy volunteers.

* Corresponding author. Present address: VaxInnate Inc., 3 Cedar Brook Dr., Cranbury, NJ 08512. Phone: (609) 860-2260. Fax: (609) 860-2289. E-mail: david.taylor{at}vaxinnate.com. Address for reprint requests: Medical Affairs, Salix Pharmaceuticals, Inc., 1700 Perimeter Park Drive, Morrisville, NC 27560. Phone: (919) 862-1015. Fax: (919) 228-4215. E-mail: sara.turner{at}salix.com

{triangledown} Published ahead of print on 17 December 2007.

Antimicrobial Agents and Chemotherapy, March 2008, p. 1179-1181, Vol. 52, No. 3
0066-4804/08/$08.00+0     doi:10.1128/AAC.01108-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Finegold, S. M., Molitoris, D., Vaisanen, M.-L. (2009). Study of the In Vitro Activities of Rifaximin and Comparator Agents against 536 Anaerobic Intestinal Bacteria from the Perspective of Potential Utility in Pathology Involving Bowel Flora. Antimicrob. Agents Chemother. 53: 281-286 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»